Peking University People's Hospital, Peking University Institute of Hematology, Beijing, People's Republic of China.
Biol Blood Marrow Transplant. 2010 Nov;16(11):1567-75. doi: 10.1016/j.bbmt.2010.05.001. Epub 2010 Sep 15.
Graft-versus-host disease (GVHD) is a major obstacle to the success of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although many indicators have been used to predict GVHD, the prediction of GVHD remains very difficult. Determining how to predict the occurrence of acute GVHD (aGVHD) as exactly as possible has been a huge challenge so far. Systemic release of inflammatory cytokines during the conditioning regimen and early-phase post-HSCT plays a crucial role in the generation of aGVHD; additionally, the conditioning regimen causes the damage to the intestinal tract. Diarrhea is a common symptom of intestinal tract damage during the conditioning regimen. We therefore performed a prospective study to investigate the relationship between diarrhea related to the conditioning regimen, systemic release of inflammatory cytokines during the conditioning regimen and the early-phase post-HSCT, and the development of aGVHD. This study demonstrated that duration of diarrhea was >5.5 days, with a maximal volume >8.72 mL/kg and a mean volume of diarrhea for days -3 to 0 >7.94 mL/kg were risk factors of grade II to IV aGVHD. Diarrhea with any 1 risk factor was defined as severe diarrhea. Furthermore, this study first confirmed that the correlation between diarrhea and aGVHD was related to the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 during the conditioning regimen and during the early phase after transplantation. Our study demonstrated that diarrhea related to the conditioning regimen could be used as a marker for the prediction of aGVHD and further explain the possible mechanism underlying the linkage described here. Therefore, for the patients with severe diarrhea related to the conditioning regimen, low-dose glucocorticoid may be used to reduce the levels of inflammatory cytokine release by a damaged intestinal tract, and possibly further reduce the occurrence of aGVHD. For these patients, prophylaxis of aGVHD may be need to be adjusted individually.
移植物抗宿主病(GVHD)是异基因造血干细胞移植(allo-HSCT)成功的主要障碍。尽管已经有许多指标用于预测 GVHD,但 GVHD 的预测仍然非常困难。迄今为止,确定如何尽可能准确地预测急性 GVHD(aGVHD)的发生一直是一个巨大的挑战。预处理方案期间和 HSCT 后早期全身释放的炎症细胞因子在 aGVHD 的发生中起着至关重要的作用;此外,预处理方案会导致肠道损伤。腹泻是预处理期间肠道损伤的常见症状。因此,我们进行了一项前瞻性研究,以研究与预处理方案相关的腹泻、预处理方案期间全身炎症细胞因子的释放以及 HSCT 后早期与 aGVHD 发展之间的关系。该研究表明,腹泻持续时间>5.5 天,最大体积>8.72 mL/kg,-3 至 0 天的平均腹泻量>7.94 mL/kg/kg 是 II 级至 IV 级 aGVHD 的危险因素。任何 1 个危险因素的腹泻均定义为严重腹泻。此外,本研究首次证实,腹泻与 aGVHD 的相关性与预处理方案和移植后早期的肿瘤坏死因子(TNF)-α和白细胞介素(IL)-6 血清水平有关。我们的研究表明,与预处理方案相关的腹泻可以用作预测 aGVHD 的标志物,并进一步解释此处描述的联系的可能机制。因此,对于与预处理方案相关的严重腹泻患者,可能需要使用低剂量糖皮质激素来降低受损肠道释放炎症细胞因子的水平,并可能进一步降低 aGVHD 的发生。对于这些患者,可能需要单独调整 aGVHD 的预防。